An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Differences in sleep patterns, which can be objectively measured with wrist-worn accelerometers, are the norm among patients with lifetime psychiatric conditions.
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
This systematic review and meta-analysis of randomized controlled trials assessed the efficacy and safety of gabapentin and duloxetine for treating patients with painful diabetic peripheral neuropathy.
Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Migraine and Headache
Dr Amit Akirov examines the evidence suggesting associations between migraine and major depressive disorder (MDD).
This was a study protocol for a phase II pilot feasibility study that will assess the feasibility of ketamine for depression in patients with advanced life-limiting illnesses.